Lexaria Bioscience Corp.
For the period ended May 31, 2025. Filed Jul 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
May 31, 2025 · Filed Jul 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Recent Sales of Unregistered Equity Securities
During the quarter ended May 31, 2025, the Company issued 70,000 share purchase warrants with an exercise price of $1.25 that expire on April 24, 2030 (the “Warrants”). The Warrants are exercisable to purchase up to 70,000 shares of the common stock of the Company and were issued to nominees of H.C. Wainright & Co. LLC, pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act, and Rule 506(b) promulgated thereunder, as consideration to the placement agent for its equity financing that closed on April 28, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.